Growth Hormone Secretagogues
GHRP-6
Also known as: SK&F-110679
Mechanism & research context
Ghrelin receptor agonist studied as a research compound for GH release; produces appetite stimulation in early trials.
Safety flags
0 flagsNo curator-recorded safety flags for this entry. Absence of recorded flags is not evidence of safety. Many peptides lack adequate human data.
Research papers
16 recordsCitation links route to PubMed, Europe PMC, and PMC. Presence of a study is not endorsement. Records are refreshed from PubMed on a regular cadence; rows marked “Live search link” will resolve to a current PubMed search until a full citation has been ingested.
-
· 2026
Growth hormone releasing peptide-6 (GHRP-6) ameliorates acute lung injury and its subsequent evolvement to interstitial fibrosis.
-
· 2026 Open access
Growth Hormone-Releasing Peptides: Investigation of Their Secondary Structure, Thermal Stability, and Model Membrane Interactions.
-
· 2026 Open access
Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation.
-
· 2026 Open access
Multiple disulfide-bonded states confer extensive conformational diversity in fibrinogen.
-
· 2025
Anti-nervous necrosis virus activity of the growth hormone releasing peptide-6, GHRP-6
-
· 2025 Open access
Changes in Locomotor Activity Observed During Acute Nicotine Withdrawal Can Be Attenuated by Ghrelin and GHRP-6 in Rats.
-
· 2025 Open access
The Ghrelin Analog GHRP-6, Delivered Through Aquafeeds, Modulates the Endocrine and Immune Responses of <i>Sparus aurata</i> Following IFA Treatment.
-
· 2025 Open access
Growth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation.
-
· 2024
Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms.
-
· 2023
Inhibition of ghrelin activity by the receptor antagonist [D-Lys3]-GHRP-6 enhances hepatic fatty acid oxidation and gluconeogenesis in a growing pig model.
-
· 2021
Ghrelin antagonist D-Lys3-GHRP-6 counteract ghrelin effects in bovine cumulus-oocytes complexes matured in vitro.
-
· 2020
D-Lys-3-GHRP-6 impairs memory consolidation and downregulates the hippocampal serotonin HT1A, HT7 receptors and glutamate GluA1 subunit of AMPA receptors.
-
· 2020
Atheroprotective and atheroregressive potential of azapeptide derivatives of GHRP-6 as selective CD36 ligands in apolipoprotein E-deficient mice.
-
· 2019 Open access
Inhibition of Ghrelin Activity by Receptor Antagonist [d-Lys-3] GHRP-6 Attenuates Alcohol-Induced Hepatic Steatosis by Regulating Hepatic Lipid Metabolism.
-
· 2018
Local injection of d-lys-3-GHRP-6 in the rat amygdala, dentate gyrus or ventral tegmental area impairs memory consolidation.
-
Review · PubMed (NCBI) Live search link
PubMed literature search: GHRP-6
Run importer to populate live PubMed records. This placeholder links to a live search.
Clinical trials
1 record-
Live search Live search
Live ClinicalTrials.gov search: GHRP-6
Condition: See live results
Open on ClinicalTrials.gov ↗
Doses reported in studies
0 recordsNo study-protocol dose records have been curated for GHRP-6 yet. Absence of records is not evidence of safety — many peptides lack adequate human-trial data in the first place.
Records here are populated from public sources only (ClinicalTrials.gov protocol summaries and FDA-approved labels) and must cite a verifiable source URL. They are not added from forum posts, vendor pages, anecdotal write-ups, or social media.
These entries describe what was studied. They do not tell you what to take, how to reconstitute anything, how to fill a capsule, how often to administer, or where to obtain a compound. If you are considering use of GHRP-6, those decisions belong with a licensed clinician working from the full label or trial record — not from this summary.
Why this page does not list a dose for self-use
The "Doses reported in studies" section above (when populated) describes what was administered in a cited study or label, under medical supervision, in a specific population. It is not a dosing guide for self-use. Separately, we do not publish anecdotal or community-reported dose ranges, administration methods, vial concentrations, or capsule masses for GHRP-6. Anecdotal figures for unapproved compounds are not harm-reduction data: they lack denominators for adverse events, cannot account for individual physiology or compound purity, and normalise unsupervised use. See the safety policy for the full reasoning.
If this compound has an FDA-approved label
If a label exists, the regulator-reviewed dosing and administration information is there — read it in the context of a prescriber's evaluation.
Questions worth bringing to a clinician
- What is the evidence for this compound in someone with my history?
- What are the realistic, regulator-reviewed alternatives?
- What would you monitor, and what would make you stop?
If you have already taken a peptide and feel unwell: contact emergency services. In the United States, Poison Control is reachable 24/7 at 1-800-222-1222. Do not wait for a community thread.